On the basis of a coverage decision for anti-amyloid monoclonal antibodies recently issued by the US Centers for Medicare and Medicaid Services, Medicare will offer ‘coverage with evidence development’ to allow more information on the clinical benefits of these antibodies to be gathered. Here, we discuss the implications of this decision for future clinical trials and Alzheimer disease care.

中文翻译：

---

CMS 关于治疗阿尔茨海默病的抗淀粉样蛋白单克隆抗体的覆盖决定


根据美国医疗保险和医疗补助服务中心最近发布的抗淀粉样蛋白单克隆抗体承保决定，医疗保险将提供“证据开发承保”，以收集有关这些抗体临床益处的更多信息。在这里，我们讨论这一决定对未来临床试验和阿尔茨海默病护理的影响。